BioTerm Pharmaceuticals
Therapeutics for Preterm Labor Prevention and Labor Induction
Company Overview
Snapshot
Founded in January 2002 by Israel Shamir Lebovitz, BioTerm Pharmaceuticals operates with 1–10 employees. The company holds one patent and is currently in the Pre-Funding stage, seeking equity investment to expand management and enhance marketing and business development activities in the U.S. and Europe.
Business overview
BioTerm Pharmaceuticals is a Health Tech & Life Sciences company focused on developing therapeutics for women's health, specifically for the prevention of preterm labor and the induction of labor. The company's core products, Preventerm and Inducterm, are based on scientifically and clinically proven molecules. Preventerm is designed to block key factors in the labor process, aiming for effective multistep inhibition of enzymes to prevent preterm labor. Inducterm, conversely, works by providing collagenase to induce labor. BioTerm Pharmaceuticals operates within the Pharmaceuticals sector, targeting the healthcare market in Israel and the United States.
Strategic signal
In April 2015, BioTerm Pharmaceuticals was highlighted in an article by Pharmaceutical Intelligence, focusing on Dr. Shamir's startup. This signals the company's early recognition within the pharmaceutical industry for its innovative approach to women's health therapeutics, indicating potential interest from strategic partners or investors in its specialized drug development.
Log in to access full profile ›Company Intelligence Q&A
- What is BioTerm Pharmaceuticals' primary focus?
- BioTerm Pharmaceuticals focuses on developing therapeutics for the prevention of preterm labor and for the induction of labor, addressing critical needs in women's health.
- Who founded BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals was founded by Israel Shamir Lebovitz, who also serves as President and Chief Medical Officer.
- What are BioTerm Pharmaceuticals' key products?
- The company's key products are Preventerm, designed for the prevention of preterm labor, and Inducterm, developed for labor induction.
- What is the current operational status of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals is currently non-active, having ceased to operate in July 2019.
- In which markets does BioTerm Pharmaceuticals operate?
- BioTerm Pharmaceuticals operates in the geomarkets of Israel and the United States.